Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

13 results about "Interleukin 2" patented technology

Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a 15.5 - 16 kDa protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes. The major sources of IL-2 are activated CD4⁺ T cells and activated CD8⁺ T cells.

Masked il-2 cytokines and methods of use thereof

PendingAU2025206788A1Fc domainInterleukin II
The present invention provides, among other things, a masked cytokine comprising an interleukin 2 (IL-2) polypeptide, a VHH masking moiety, an anti-PD1 targeting moiety, and an engineered Fc domain comprising a tumor-associated protease cleavage site. In such masked cytokine, the IL-2 polypeptide is engineered to be activatable by a protease at a target site, such as in a tumor microenvironment. The VHH masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e g masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavage site in the Fc domain, the IL-2 polypeptide becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
Owner:XILIO DEVELOPMENT INC

Masked IL-2 cytokines and methods of use thereof

The present invention provides, among other things, a masked cytokine comprising an interleukin 2 (IL-2) polypeptide, a VHH masking moiety, an anti-PD1 targeting moiety, and an engineered Fc domain comprising a tumor-associated protease cleavage site. In such masked cytokine, the IL-2 polypeptide is engineered to be activatable by a protease at a target site, such as in a tumor microenvironment. The VHH masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e g masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavage site in the Fc domain, the IL-2 polypeptide becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
Owner:XILIO DEVELOPMENT INC

Pig IL-2-IFN-alpha-T alpha 1 interferon fusion protein as well as preparation method and application thereof

The invention belongs to the field of biotechnology and veterinary immune preparations, and relates to a porcine IL-2-IFN-alpha-T alpha 1 interferon fusion protein and a preparation method and application thereof.The amino acid sequence of the interferon fusion protein is shown as SEQ ID NO.1, and the interferon fusion protein is composed of recombinant porcine interleukin 2, flexible connecting peptide, recombinant porcine alpha interferon, flexible connecting peptide and thymosin; the amino acid sequence of the recombinant porcine interleukin 2 is as shown in SEQ ID NO. 2; the amino acid sequence of the recombinant porcine alpha interferon is as shown in SEQ ID NO.3; the amino acid sequence of the thymosin is as shown in SEQ ID NO. 4; the amino acid sequence of the flexible connecting peptide is as shown in SEQ ID NO.5. The porcine IL-2-IFN-alpha-T alpha 1 interferon fusion protein provided by the invention has good biological activity and no cytotoxicity, has high antiviral property and immune regulation function, and can effectively improve the antiviral ability of pigs.
Owner:HENAN AGRICULTURAL UNIVERSITY

Interleukin 2 (il-2) and CD123 NK cell engager combination therapy

The present disclosure relates to methods of treating cancer with the combination of a binding protein comprising a first and a second antigen binding domain (ABD), wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46, and an interleukin 2 (IL-2) polypeptide.
Owner:SANOFI SA(FR)

Masked il-2 cytokines and methods of use thereof

The present invention provides, among other things, a masked cytokine comprising an attenuated interleukin 2 (IL-2) polypeptide, a VHH masking moiety, a carrier moiety, and an anti-PD1 targeting moiety. In some embodiments, the IL-2 polypeptide is engineered with a proteolytically cleavable linker comprising to be activated at a target site, such as in a tumor microenvironment, by protease activity. The VHH masking moiety blocks, occludes, inhibits (e.g., reduces), or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. When the cleavable linker is proteolytically cleaved at the target site, the IL-2 polypeptide is activated, which enables it to bind to its cognate receptor or protein with increased affinity.
Owner:XILIO DEVELOPMENT INC

Human interleukin 2 variant and application thereof

The invention relates to a human interleukin-2 (IL-2) variant as well as a derivative and application thereof. The IL-2 variants are obtained by authorized computing software, the affinity to the high affinity receptor IL2R [alpha] [beta] [gamma] being reduced or eliminated while preserving the affinity to the medium affinity receptor IL2R [beta] / [gamma]. The disclosure also relates to human antibody fragment fusion proteins comprising the IL-2 variants, which enhance the activity of the interleukin 2 variants.
Owner:董明晖

Interleukin 2 (il-2) and CD123 NK cell engager combination therapy

The present disclosure relates to methods of treating cancer with the combination of a binding protein comprising a first and a second antigen binding domain (ABD), wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46, and an interleukin 2 (IL-2) polypeptide.
Owner:SANOFI SA(FR) +4

An interleukin 2 mutant

The present application provides a kind of interleukin 2 mutant, fusion protein, antibody or conjugate comprising the mutant and pharmaceutical composition comprising the mutant, fusion protein, antibody or conjugate. Compared with wild type interleukin 2, the mutant eliminates the binding with IL-2R alpha, reduces the binding with IL-2R beta gamma dimer, but maintains the stimulation of tumor immune cells, including but not limited to T cells and NK cells proliferation. The IL-2 mutant of the present application eliminates the affinity for high affinity IL-2 receptor, while reducing the affinity for medium affinity IL-2 receptor. The interleukin 2 mutant of the present application is more suitable for fusion protein, antibody conjugate. The mutation site of the interleukin 2 mutant of the present application is very few relative to wild type interleukin 2, so the potential immunogenicity is very low. At the same time, there is no various side effects produced by immunotherapy with natural IL-2.
Owner:SHANGHAI GP BIOTECH CO LTD

Modified interleukin 2 (IL-2) polypeptides, conjugates, and uses thereof

The present disclosure relates to modified interleukin 2 (IL-2) polypeptides, polynucleotides, e.g., DNA, RNA, or viral vectors, encoding and configured to express the modified IL-2 polypeptides in vitro and / or in vivo, conjugates comprising the modified IL-2 polypeptides, and uses thereof.
Owner:ANOCON PHARMACEUTICAL CO LTD

Anti-PD-1 and mutant IL-2 immune complex preparations

PendingJP2026510404APowder deliveryPeptide/protein ingredientsAntiendomysial antibodiesImmune complex deposition
The present invention relates to a formulation of an immune complex ("αPD-1 / IL2m") comprising a recombinant anti-programmed cell death receptor 1 (PD-1) antibody and mutant interleukin 2 (IL2), particularly a stable liquid formulation, a method for preparing the formulation, and the use of the formulation in the treatment and / or prevention of disease.
Owner:フォートビタ バイオロジクス(シンガポール)プライベート リミティド